AZA + APG1252 for High-Risk AML

This trial explores a new treatment for individuals with high-risk acute myeloid leukemia (AML), a cancer affecting blood and bone marrow. The trial tests a combination of two drugs, APG1252 (a potential new drug) and Azacitidine, to assess their safety and effectiveness together. Participants are divided into groups: one for those whose AML has returned or not responded to other treatments, and another for those newly diagnosed with AML. Individuals with frequent AML relapses or a new diagnosis may be suitable for this trial. As a Phase 1, Phase 2 trial, the research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get specific guidance based on your situation.

Research has shown that azacitidine, when combined with other treatments, is generally safe for patients with acute myeloid leukemia (AML). Specifically, studies have found that pairing azacitidine with venetoclax can slow disease progression and is well-tolerated by patients, meaning they can undergo treatment without severe side effects.

Conversely, APG1252 is a newer treatment still under investigation. This trial is in its early stages, focusing on the safety of APG1252 for individuals. Since the research is in its infancy, the primary goal is to observe patient reactions and identify any side effects.

Researchers are excited about the combination of Azacitidine and APG1252 for high-risk acute myeloid leukemia (AML) because it offers a novel approach compared to standard treatments like chemotherapy. APG1252 is a new agent that targets specific proteins involved in cell death, potentially making it more effective at killing cancer cells. Combining this with Azacitidine, which is already used to treat AML by affecting DNA and RNA, could enhance the overall treatment effectiveness and provide hope for patients who have relapsed or have not been treated before. This innovative combination has the potential to improve outcomes by working synergistically to attack cancer cells in multiple ways.

This trial will evaluate the combination of Azacitidine and APG1252 for high-risk acute myeloid leukemia (AML). Research has shown that azacitidine, when combined with other treatments, can improve outcomes for AML patients. For example, combining azacitidine with venetoclax reduced the risk of disease progression by 39%. Patients receiving this combination lived longer without disease progression and responded better than those receiving traditional chemotherapy. APG1252, a newer treatment in this trial, targets a protein called BCL-XL, which aids cancer cell survival, suggesting it could complement azacitidine effectively. Early studies indicate that similar combinations are promising and have manageable safety profiles.¹⁴⁶⁷⁸